Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Assets Average (2016 - 2026)

Insight Molecular Diagnostics' Assets Average history spans 6 years, with the latest figure at $34.8 million for Q4 2025.

  • On a quarterly basis, Assets Average fell 33.81% to $34.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $34.8 million, a 33.81% decrease, with the full-year FY2025 number at $30.4 million, down 44.68% from a year prior.
  • Assets Average hit $34.8 million in Q4 2025 for Insight Molecular Diagnostics, down from $47.2 million in the prior quarter.
  • Over the last five years, Assets Average for IMDX hit a ceiling of $172.9 million in Q3 2021 and a floor of $34.8 million in Q4 2025.
  • Historically, Assets Average has averaged $99.1 million across 5 years, with a median of $84.9 million in 2023.
  • Biggest five-year swings in Assets Average: soared 189.68% in 2021 and later crashed 48.5% in 2023.
  • Tracing IMDX's Assets Average over 5 years: stood at $164.0 million in 2021, then decreased by 21.49% to $128.7 million in 2022, then plummeted by 39.22% to $78.2 million in 2023, then plummeted by 32.71% to $52.6 million in 2024, then crashed by 33.81% to $34.8 million in 2025.
  • Business Quant data shows Assets Average for IMDX at $34.8 million in Q4 2025, $47.2 million in Q3 2025, and $55.4 million in Q2 2025.